12.08.25 -- The Future Of Biotech Outsourcing: Essential Skills For Program Managers

By partnering with a single supplier that manages the entire manufacturing value chain, companies can minimize risk, enhance operational flexibility, streamline processes, and accelerate their time to market.

A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

This roundtable weaves together diverse perspectives from industry leaders, researchers, and patient advocates, offering a multifaceted look at what it will take to create a path forward in rare disease drug development.

Platform-based manufacturing uses standardized, pre-qualified workflows and analytics that reduce variability, simplify regulatory submissions, and accelerate the path to commercial success.

Explore what nitrosamines are, why testing matters, and how we're able to deliver high-confidence solutions through advanced science and industry-leading expertise.

By leveraging cells equipped with an existing TARGATT™ landing pad, we demonstrate how inducible expression can be efficiently achieved within just 4-6 weeks after donor plasmid creation.

Adopt next-generation, physiologic T cell activation strategies to enable faster, more consistent, and scalable CAR-T manufacturing that improves expansion, persistence, and patient access.

Advancing cell and gene therapies for rare pediatric diseases requires overcoming unique challenges in trial design, patient access, and long-term follow-up.

Improved iPBMC manufacturing boosts TIL therapy reliability, safety, and affordability through donor screening, process refinements, and performance-based cell selection.

Ensure fast, reliable, temperature-controlled logistics with a global infrastructure designed to protect critical biologic materials and keep development programs running smoothly and on schedule.